Rigel publishes final ARROW trial data for pralsetinib in lung cancer
Go back to Rigel publishes final ARROW trial data for pralsetinib in lung cancer| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 36.24 +0.51 (1.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.73 | 52 Week High | $4.38 | |||
| Open | $35.85 | 52 Week Low | $1.88 | |||
| Day High | $36.50 | P/E | N/A | |||
| Day Low | $35.70 | EPS | $-1.12 | |||
| Volume | 84,861 | |||||
